In 2020 and 2021 Concept Foundation worked closely with Centro de Estudios de Estado y Sociedad (CEDES) in Argentina, to conduct a market assessment to identify possible barriers and challenges to accessing quality assured and affordable medical abortion supplies...
Main activities and impact. While most of 2020 was disrupted by the COVID-19 pandemic, we were able to generate new projects and grants towards the end of the year. Our maternal health portfolio expanded significantly in 2020 while we continued with our...
WHO publishes for the first time a set of dedicated regulatory guidelines for national medicines authorities in low-and middle-income countries (LMICs) to evaluate and set quality standards for oxytocin, an essential maternal health drug used for the prevention and...
Haemorrhage continues to be the most significant direct cause of maternal death, accounting for 661 000 deaths worldwide between 2003 and 2009. Most of these deaths occur during the immediate postpartum period and are due to uterine atony, a condition characterised...
In our recent publication, Concept Foundation reports on the regulatory standards and processes for over the counter (OTC) availability of hormonal contraception and drugs for medical abortion in Egypt, Jordan, Morocco, Lebanon and Tunisia. The main conclusions...
As part of the ACCELERATING INNOVATION FOR MOTHERS (AIM) project, in partnership with the Bill & Melinda Gates Foundation, we published the report “Medicines for Pregnancy Specific Conditions: Research, Development and Market Analysis”. It provides the current...
The use of substandard and counterfeit medicines (SCM) leads to significant health and economic consequences, like treatment failure, rise of antimicrobial resistance, extra expenditures of individuals or households and serious adverse drug reactions including...
Postpartum haemorrhage (PPH) is a leading cause of maternal mortality, globally, disproportionately affecting low and middle-income countries (LMICs). It also contributes significanlty to maternal morbidity and long-term disability. Preventing PPH is essential for...
One of the key barriers limiting procurement and access to essential reproductive health medicines is affordability in low-resource settings. The price of a mifepristone/misoprostol (combi-pack) is currently marked by significant variances. Concept Foundation has...
The WHO ACTION-I Trial was a multi-country efficacy trial of antenatal dexamethasone for women at risk of imminent preterm birth in low-resource countries. The trial randomised 2,852 women and their 3070 babies at 29 hospitals In Bangladesh, India, Kenya, Nigeria...
